Top

Published in:

01-10-2018 | Original Article

Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington’s disease

Authors: Surekha Ramachandran, Sumathi Thangarajan

Published in: Metabolic Brain Disease | Issue 5/2018

Abstract

Defect in gene transcription, excitotoxicity, neuroinflammation and oxidative stress are the dominant disease process that causes striatal cell loss with motor abnormalities in Huntington’s disease (HD). Homogeneous pathological reminiscent of HD was extrapolated in the present study using a potent mitochondrial toxin, 3-Nitropropionic acid (3-NP). Administration of 3-NP for 14 days in the present study portends glial cell activation, N-methyl-D-aspartate (NMDA) receptor stimulation, neuroinflammation and motor deficits. The therapeutic strategy in the present study was improvised by formulating thymoquinone, a biologically active compound into a colloidal carrier namely solid lipid nanoparticles. Treatment with 10 and 20 mg/kg b.w of thymoquinone loaded solid lipid nanoparticles (TQ-SLNs) and 80 mg/kg b.w of thymoquinone suspension (TQ-S) showed a significant (P < 0.01) improvement in ATPases function in 3-NP induced animals than TQ-S (40 mg/kg b.w) treated group. TQ-SLNs (10 and 20 mg/kg) treatment also attenuated the overexpression of glial fibrillary acidic protein (GFAP), pro-inflammatory cytokines and p-p65 NFκB nuclear translocation in 3-NP exposed animals. Further, TQ-SLNs treatment desensitizes NR2B-subtype NMDA receptor, improves tyrosine hydroxylase (TH) immune reactive neurons and ameliorated the motor abnormalities in 3-NP intoxicated animals than TQ-S treated group. Hence, the study signifies that the treatment with lower doses of nanoformulated thymoquinone than thymoquinone suspension can efficiently culminate 3-NP induced HD progression in the striatum of male wistar rats.

Aquib M, Najmi AK, Akthar M (2015) Antidepressant effect of thymoquinone in animal models of depression. Drug Res (Stuttg) 65:490–494

Bedard C, Wallman MJ, Pourcher E, Gould PV, Parent A, Parent M (2011) Serotonin and dopamine striatal innervation in Parkinson’s disease and Huntington’s chorea. Parkinsonism Relat Disord 17:593–598CrossRefPubMed

Bilney B, Morris ME, Churchyard A, Chiu E, Georgiou-Karistianis N (2005) Evidence for a disorder of locomotor timing in Huntington's disease. Mov Disord 20:51–57CrossRefPubMed

Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59:454–477CrossRefPubMed

Borges VC, Rocha JBT, Nogueira CW (2005) Effect of diphenyl diselenide, diphenyl ditelluride and ebselenon cerebral Na⁺K⁺ATPase activity in rats. Toxicology 215:191–197CrossRefPubMed

Brini M, Carafoli E (2009) Calcium pumps in health and disease. Physiol Rev 89:1341–1378CrossRefPubMed

Carageorgiou H, Pantos C, Zarros A, Stolakis V, Mourouzis I, Cokkinos D, Tsakiris S (2007) Changes in acetylcholinesterase, Na⁺K⁺ ATPase, and Mg²⁺ ATPase activities in the frontal cortex and the hippocampus of hyper and hypothyroid adult rats. Metab Clin Exp 56:1104–1110CrossRefPubMed

Cattaneo E (2003) Dysfunction of wild type huntingtin in Huntington disease. J News Physiol Sci 18:34–37

Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. Anal Biochem 162:156–159CrossRefPubMed

Cirillo G, Maggio N, Bianco MR, Vollono C, Sellitti S, Papa M (2010) Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. Neurochem Int 56:152–160CrossRefPubMed

Cote SL, Ribeiro-Da-Silva A, Cuello AC (1993) Immunocytochemistry II. John Wiley and Sons, New York

Damiano M, Galvan L, Déglon N, Brouillet E (2010) Mitochondria in Huntington's disease. Biochim Biophys Acta 1802:52–61CrossRefPubMed

Delval A, Krystkowiak P, Delliaux M, Dujardin K, Blatt JL, Destée A, Derambure P, Defebvre L (2008) Role of attentional resources on gait performance in Huntington’s disease. Mov Disord 23:684–689CrossRefPubMed

Fernagut PO, Diguet E, Labattu B, Tison F (2002) A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 113:123–130CrossRefPubMed

Fiske CK, Subbarow Y (1925) The colorimetric determination of phosphorus. J Biol Chem 66:376–406

Frautschy SA, Cole GM (2009) Bioavailable curcuminoid formulations for treating Alzheimer’s disease and other age-related disorders. United states US:2009/0324703 A1

Gilhotra N, Dhingra D (2011) Thymoquinone produced antianxiety-like effects in mice through modulation of GABA and NO levels. Pharmacol Rep 63:660–669CrossRefPubMed

Gökce EC, Kahveci R, Gökce A, Cemil B, Aksoy N, Sargon MF, Kısa Ü, Erdoğan B, Güvenç Y, Alagöz F, Kahveci O (2016) Neuroprotective effects of thymoquinone against spinal cord ischemia-reperfusion injury by attenuation of inflammation, oxidative stress, and apoptosis. J Neurosurg Spine 24:949–959CrossRefPubMed

Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang D-M (2002) Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80:589–597CrossRefPubMed

HDCRG (The Huntington's Disease Collaborative Research Group) (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971–983CrossRef

Hjerten S, Pan H (1983) Purification and characterization of two forms of low affinity calcium ion ATPase from erythrocyte membrane. Biochim Biophys Acta 755:457–466CrossRef

Hosseinzadeh H, Parvardeh S (2004) Anticonvulsant effects of thymoquinone, the major constituent of Nigella sativa seeds in mice. Phytomedicine 11:56–64CrossRefPubMed

Houghton PJ, Zarka R, de las Heras B, Hoult JR (1995) Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leucocytes and membrane lipid peroxidation. Planta Med 61:33–36CrossRefPubMed

Ismail N, Ismail M, Abu Bakar MF, Azmi NH, Basri H, Abdullah MA (2016) Modulation of hydrogen peroxide-induced oxidative stress in human neuronal cells by thymoquinone-rich fraction and thymoquinone via transcriptomic regulation of antioxidant and apoptotic signaling genes. Oxid Med Cell Longevity Article ID 2528935:1–15CrossRef

Jamwal S, Kumar P (2016) Spermidine ameliorates 3-nitropropionic acid (3-NP)-induced striatal toxicity: possible role of oxidative stress, neuroinflammation, and neurotransmitters. Physiol Behav 155:180–187CrossRefPubMed

Keyhanmanesh R, Gholamnezhad Z, Boskabady MH (2014) The relaxant effect of Nigella sativa on smooth muscles, its possible mechanisms and clinical applications. Iran J Basic Med Sci 17:939–949PubMedPubMedCentral

Khan A, Vaibhav K, Javed H, Khan MM, Tabassum R, Ahmed ME, Srivastava P, Khuwaja G, Islam F, Siddiqui MS, Shafi MM, Islam F (2012) Attenuation of Abeta-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Mol Cell Biochem 369:55–65CrossRefPubMed

Kumar P, Kumar A (2009) Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog Neuro-Psychopharmacol Biol Psychiatry 33:100–108CrossRef

Kumar P, Padi SS, Naidu PS, Kumar A (2007) Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol 21:297–306CrossRefPubMed

Kumar P, Kalonia H, Kumar A (2010) Possible nitric oxide modulation in protective effect of FK-506 against 3-nitropropionic acid-induced behavioral, oxidative, neurochemical, and mitochondrial alterations in rat brain. Drug Chem Toxicol 33:377–392CrossRefPubMed

Kumar P, Kalonia H, Kumar A (2011) Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington’s disease-like symptoms in rats: protective effect of licofelone. Br J Pharmacol 164:644–654CrossRefPubMedPubMedCentral

Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN (2002) Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 99:2356–2361CrossRefPubMedPubMedCentral

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMed

Möller T (2010) Neuroinflammation in Huntington’s disease. J Neural Transm (Vienna) 117:1001–1008CrossRef

Nazari M, Khodadadi H, Fathalizadeh J, Hassanshahi G, Bidaki R, Ayoobi F, Hajebrahimi B, Bagheri F, Arababadi MK (2013) Defective NF-kB transcription factor as the mediator of inflammatory responses: a study on depressed iranian medical students. Clin Lab 59:827–830PubMed

Novak MJ, Tabrizi SJ (2010) Huntington's disease. BMJ 341:34–40

Nowak G, Szewczyk B, Wieronska M (2003) Antidepressant like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 61:159–164CrossRefPubMed

Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Al Bawab A (2012) Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Deliv 9:371–377CrossRef

Ohinishi T, Suzuki T, Suzuki Y, Ozawa K (1982) A comparative study of plasma membrane magnesium ion ATPase activities in normal, regenerating and malignant cells. Biochim Biophys Acta 684:67–74CrossRef

Ramachandran S, Thangarajan S (2016) A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington’s disease-like symptoms in wistar rats. Chem Biol Interact 256:25–36CrossRefPubMed

Sanui H, Rubin H (1982) The role of magnesium in cell proliferation and transformation. In: Boynton AL, McKochan WL, Whitfield JP (eds) Ions cell proliferation and Cancer, academic press, New York, pp 517–537CrossRef

Schreiber E, Harshman K, Kemler I, Malipiero U, Schaffner W (1990) Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. Nucleic Acids Res 18:5495–5503CrossRefPubMedPubMedCentral

Selkoe DJ, Salazar FJ, Abraham C, Kosik KS (1982) Huntington’s disease: changes in striatal proteins reflect astrocytic gliosis. Brain Res 245:117–125CrossRefPubMed

Surekha R, Sumathi T (2016) An efficient encapsulation of thymoquinone using solid lipid nanoparticle for brain targeted drug delivery: physicochemical characterization, pharmacokinetics and bio-distribution studies. IJPCR 8:1616–1624

Surekha R, Aishwarya V, Sumathi T (2014) Thymoquinone loaded solid lipid nanoparticle: formulation, characterization and in-vitro cell viability assay. Int J Pharm Bio Sci 6:449–464

Teunissen CE, Steinbusch HW, Angevaren M, Appels M, de Bruijn C, Prickaerts J, de Vente J (2001) Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. Neuroscience 105:153–167CrossRefPubMed

Towbin H, Staehelin T, Gordon J (1992) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Biotechnology 24:145–149PubMed

Túnez I, Tasset I, Pérez-de la Cruz V, Santamaría A (2010) 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington’s disease: past, present and future. Molecules 15:878–916CrossRefPubMed

Vis JC, Verbeek MM, de Waal RM, ten Donkelaar HJ, Kremer B (2001) The mitochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum. Neuropathol Appl Neurobiol 27:68–76CrossRefPubMed

Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron 33:849–860CrossRefPubMed

Title: Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington’s disease
Authors: Surekha Ramachandran
Sumathi Thangarajan
Publication date: 01-10-2018
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 5/2018
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-018-0252-0

At a glance: The STEP trials

Springer Medicine

Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

A high-fat diet induced NMRI mouse model of metabolic syndrome: focus on brain-derived neurotrophic factor (BDNF)

Novel action of vinpocetine in the prevention of paraquat-induced parkinsonism in mice: involvement of oxidative stress and neuroinflammation

Impact of swimming exercise on inflammation in medullary areas of sympathetic outflow control in spontaneously hypertensive rats

Protective effects of Scutellaria baicalensis Georgi extract on D-galactose induced aging rats

Neuroinflammation in acute hepatic encephalopathy rats: imaging and therapeutic effectiveness evaluation using 11C-PK11195 and 18F-DPA-714 micro-positron emission tomography

Modulation of miR-139-5p on chronic morphine-induced, naloxone-precipitated cAMP overshoot in vitro